DOCSLIB.ORG

British Columbia Laboratory Requisition This Requisition Form, When Completed, Constitutes a Referral to Lifelabs/BC Biomedical Laboratories Physicians

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
British Columbia Laboratory Requisition This Requisition Form, When Completed, Constitutes a Referral to Lifelabs/BC Biomedical Laboratories Physicians 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany British Columbia Laboratory Requisition This requisition form, when completed, constitutes a referral to LifeLabs/BC Biomedical Laboratories physicians. Please ship NON-PRENATAL SAMPLES to: LIFELABS • Attn: CDS Department 100 International Boulevard• Toronto ON• M9W6J6 Attention Patient: Please visit your nearest LifeLabs or BCBiomedical Patient Service Centre for sample collection TO BE COMPLETED BY ORDERING DOCTOR AND PATIENT Patient Name (from CareCard or other ID) Gender Date of Birth Male Female YEAR MONTH DAY Patient Address Telephone Number Patient Email Bill to Patient: ✓(no charge at PSC) Doctor Name MSC # Organization Address Fax Number Telephone Number Email Copy to Genetic Test - mnemonic ACG (Blood sample 2 x 4mL EDTA) Genetic Test (Pediatric) - mnemonic CEN (Blood sample 1 x 2mL EDTA) Genetic Test (Other Sample Type) - mnemonic OCG (other sample type) PRENATAL SAMPLES: Please ship directly to CENTOGENE. Privacy Statement: The personal information collected on this form is collected under the authority of the Personal Information Protection act. The personal information is used to provide medical services requested on this requisition. The information collected is used for quality assurance management and disclosed to healthcare practitioners involved in providing care or when required or permitted by law. Personal information is protected from unauthorized use and disclosure in accordance with the Personal Information Protection act and when applicable the e-health act and/or the Freedom of Information and Protection of Privacy act and may be used and disclosed only as provided by those acts. our privacy policies are available at www.bcbio.com and www.lifelabs.com. Genetic Testing Consent I understand that a DNA specimen will be sent to LifeLabs for genetic testing. My physician has told me about the condition(s) being tested and its genetic basis. I am aware that correct information about the relationships between my family members is important. I agree that my specimen and personal health information may be sent to Centogene AG at their lab in Germany (address below). To ensure accurate testing, I agree that the results of any genetic testing that I have had previously completed by Centogene AG may be shared with LifeLabs. I understand that LifeLabs will contact me for a new specimen if a test result cannot be provided from the original specimen. I agree that a copy of my results will be sent to my ordering physician. I further agree that for any test(s) performed by Centogene AG, a copy of my results will also be sent to LifeLabs. I understand that once the requested test(s) has/have been completed, any remaining sample will be stored at the testing laboratory. OPTIONAL CONSENT: Please Initial where appropriate I agree that my de-identified sample may be used for product development or research purposes. I understand that I will not receive any royalties, resultant payments, benefits or rights to products or discoveries. I do not want my remaining sample to be stored. Please destroy any remaining sample once the final report has been issued. I have had genetic testing completed in the past by the following laboratories: I agree that Centogene AG and LifeLabs may obtain a copy of these genetic test results from the testing laboratory. Patient/Substitute Decision Maker: Signature: Date(YY/MM/DD): Printed name: relationship to person being tested: OR I certify that verbal consent was obtained from the patient /substitute decision maker for the requested genetic testing Signature: Date(YY/MM/DD): For appointments at LifeLabs Patient Service Centres please call 1-855-412-4495. For appointments at BC Biomedical Patient Service Centres please call 1-877-507-5595 Date Doctor Signature YEAR MONTH DAY TO BE COMPLETED BY LABORATORY STAFF Date /Time of Collection Phlebotomist YEAR MONTH DAY **Laboratory Staff: Photocopy Requisition and include one copy with samples in box** LL-GCG-001 - Ver 2 – JAN 2015 Page 1/5 The minimum amount of patient information is collected for provision of the service requested. This information is considered confidential and privileged. Unauthorized use and disclosure is prohibited. RequisitionV3 Jan2015 GENETIC TESTING REQUISITION TUMORAL & HEMATOLOGICAL DISORDERS 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany Patient Name: Patient DOB (YYYY/MM/DD): Sample Type: □ *Blood (EDTA: 5mL for single gene, 10mL for panel) □ DNA (single gene:1-10ug, panel 10-100ug) *Filter card (1 card/30 exons: Available by request) □ LifeLabs Demographic □ Saliva (Oragene OG-510: Available by request) Label □ Fibroblast/Skin Biopsy (0.5cm2) □ Cultured cells (1 flask, min 25cm2, 80-90% confluent) □ **Amniotic fluid (10mL) □ **Chorionic Villus (10 villi, cleaned) □ Other: _________________________________________________________ * Exact amount depends on size of panel, see www.centogene.com ** Please contact us prior to sending cells Billing Status: □ Ministry of Health Approved (Approval letter attached) □ Ministry of Health Approval Pending □ Institution (Complete information below) □ Private Pay (Complete information below) Institution Billing ONLY: Institution Name: ___________________________________ Contact Name: _____________________________ Address: Phone: ( ) - Fax: ( ) - Email: _______________________________ Private Pay ONLY: Credit Card Type: □ MasterCard □ Visa Card Number_________________________________________ Exp Date(MM/YY)_____________________ Name (as it appears on credit card)__________________________________________________________ I understand that my credit card will be charged for the full amount of testing not paid for by my provincial health plan Cardholder Signature: _______________________________________ Date (DD/MM/YYYY)________________ Patient Information: Gender: □M □ F Ethnicity: ___________________________ Additional patient medical information: Relevant Family history: Have other family members submitted samples to Centogene for analysis? □Y □ N If yes, Name:_______________________ Relationship to patient _________________________ DOB (YYYY/MM/DD):____________________ Familial Mutation Testing Gene:______________ Mutation (HGVS):_____________________ □Familial Report attached Testing Instructions: (ex: Reflex order) ** PLEASE INCLUDE A COPY OF REQUISITION WITH SAMPLES ** Page 2/5 The minimum amount of patient information is collected for provision of the service requested. This information is considered confidential and privileged. Unauthorized use and disclosure is prohibited. RequisitionV3 Jan2015 GENETIC TESTING REQUISITION TUMORAL & HEMATOLOGICAL DISORDERS 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany Patient Name: Patient DOB (YYYY/MM/DD): Please indicate requests for Hot Spot (H), Sequencing (S), and/or Deletion/Duplication (D) analysis Disorders of Skin, Teeth, & Hair NGS Panels: S Congenital ichthyosis panel (ABCA12, ALOX12B, ALOXE3, CERS3, CYP4F22, LIPN, NIPAL4, PNPLA1, TGM1) S Epidermolysis bullosa panel (COL17A1, LAMA3, LAMB3, LAMC2) Single genes: H D S Acne inversa familial type 3 (PSEN1) D S Epidermolytic palmoplantar keratoderma (KRT9) Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis and D S Adams-Oliver syndrome type 1 (ARHGAP31) D S hyper IgE (DSG1) D S Adams-Oliver syndrome type 2 (DOCK6) D S Erythrokeratodermia variabilis et progressiva (GJB3) D S Adams-Oliver syndrome type 3 (RBPJ) D S Erythrokeratodermia variabilis et progressiva (GJB4) D S Ankyloblepharon-ectodermal defects-cleft lip/palate (TP63) D S Focal dermal hypoplasia (PORCN) D S Albinism oculocutaneous nonsyndromic (SLC24A5) D S Griscelli syndrome type 1 (MYO5A) H D S Albinism, oculocutaneous type 1A (TYR) D S Griscelli syndrome type 3 (MLPH) H D S Albinism, oculocutaneous type 1B (TYR) D S Haim-Munk syndrome (CTSC) H D S Albinism, oculocutaneous type 2 (OCA2) D S Hyaline fibromatosis syndrome (ANTXR2) H D S Albinism, oculocutaneous type 2 (OCA2) D S Hypotrichosis Type 7 (LIPH) D S Albinism, oculocutaneous type 3 (TYRP1) D S Ichthyosiform erythroderma, congenital, nonbullous type 1 (ALOX12B) H D S Albinism, oculocutaneous type 4 (SLC45A2) D S Ichthyosiform erythroderma, congenital, nonbullous type 1 (ALOXE3) D S Albinism oculocutaneous type 5 (C10ORF11) D S Ichthyosiform erythroderma, congenital, nonbullous type 1 (NIPAL4) H D S Amelogenesis imperfecta (DLX3) D S Ichthyosiform erythroderma, congenital, nonbullous type 1 (TGM1) D S Autosomal dominant woolly hair with hypotrichosis (KRT71) D S Ichthyosis congenita, Harlequin fetus type (ABCA12) D S Autosomal dominant woolly hair with hypotrichosis (KRT74) D S Ichthyosis congenital, autosomal recessive type 9 (CERS3) D S Bjornstad syndrome (BCS1L) D S Ichthyosis congenital, autosomal recessive PNPLA1 related (PNPLA1) Cerebral dysgenesis, neuropathy, ichthyosis, palmoplantar keratoderma syndrome D S (SNAP29) D S Ichthyosis follicularis, atricia, and photophobia syndrome (MBTPS2) D S Chediak-Higashi syndrome (LYST) D S Ichthyosis prematurity syndrome (SLC27A4) D S CHIME syndrome (PIGL) H D S Ichthyosis vulgaris (FLG) D S Corneal intraepithelial dyskeratosis and ectodermal dysplasia (NLRP1) D S Ichthyosis, bullous type (KRT2) D S Craniosynostosis and dental anomalies (IL11RA) D S Ichthyosis, lamellar type 1 (TGM1) D S Cutis laxa type 1B (EFEMP2) D S Ichthyosis, lamellar type 2 (ABCA12) D S Cutis laxa type 2B (PYCR1) D S Ichthyosis, lamellar type 3 (CYP4F22) D S Cutis laxa
Load more

Recommended publications
  • Blueprint Genetics Craniosynostosis Panel
    Craniosynostosis Panel Test code: MA2901 Is a 38 gene panel that includes assessment of non-coding variants. Is ideal for patients with craniosynostosis. About Craniosynostosis Craniosynostosis is defined as the premature fusion of one or more cranial sutures leading to secondary distortion of skull shape. It may result from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). Premature closure of the sutures (fibrous joints) causes the pressure inside of the head to increase and the skull or facial bones to change from a normal, symmetrical appearance resulting in skull deformities with a variable presentation. Craniosynostosis may occur in an isolated setting or as part of a syndrome with a variety of inheritance patterns and reccurrence risks. Craniosynostosis occurs in 1/2,200 live births. Availability 4 weeks Gene Set Description Genes in the Craniosynostosis Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ALPL Odontohypophosphatasia, Hypophosphatasia perinatal lethal, AD/AR 78 291 infantile, juvenile and adult forms ALX3 Frontonasal dysplasia type 1 AR 8 8 ALX4 Frontonasal dysplasia type 2, Parietal foramina AD/AR 15 24 BMP4 Microphthalmia, syndromic, Orofacial cleft AD 8 39 CDC45 Meier-Gorlin syndrome 7 AR 10 19 EDNRB Hirschsprung disease, ABCD syndrome, Waardenburg syndrome AD/AR 12 66 EFNB1 Craniofrontonasal dysplasia XL 28 116 ERF Craniosynostosis 4 AD 17 16 ESCO2 SC phocomelia syndrome, Roberts syndrome
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • Blueprint Genetics Comprehensive Growth Disorders / Skeletal
    Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Test code: MA4301 Is a 374 gene panel that includes assessment of non-coding variants. This panel covers the majority of the genes listed in the Nosology 2015 (PMID: 26394607) and all genes in our Malformation category that cause growth retardation, short stature or skeletal dysplasia and is therefore a powerful diagnostic tool. It is ideal for patients suspected to have a syndromic or an isolated growth disorder or a skeletal dysplasia. About Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders This panel covers a broad spectrum of diseases associated with growth retardation, short stature or skeletal dysplasia. Many of these conditions have overlapping features which can make clinical diagnosis a challenge. Genetic diagnostics is therefore the most efficient way to subtype the diseases and enable individualized treatment and management decisions. Moreover, detection of causative mutations establishes the mode of inheritance in the family which is essential for informed genetic counseling. For additional information regarding the conditions tested on this panel, please refer to the National Organization for Rare Disorders and / or GeneReviews. Availability 4 weeks Gene Set Description Genes in the Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ACAN# Spondyloepimetaphyseal dysplasia, aggrecan type, AD/AR 20 56 Spondyloepiphyseal dysplasia, Kimberley
    [Show full text]
  • Case Report Immunodeficiency in a Child with Rapadilino Syndrome: a Case Report and Review of the Literature
    CORE Metadata, citation and similar papers at core.ac.uk Provided by MUCC (Crossref) Hindawi Publishing Corporation Case Reports in Immunology Volume 2015, Article ID 137368, 4 pages http://dx.doi.org/10.1155/2015/137368 Case Report Immunodeficiency in a Child with Rapadilino Syndrome: A Case Report and Review of the Literature M. M. G. Vollebregt,1 A. Malfroot,1 M. De Raedemaecker,2 M. van der Burg,3 and J. E. van der Werff ten Bosch4 1 Department of Pediatrics, University Hospital Brussels, 1090 Brussels, Belgium 2DepartmentofGenetics,UniversityHospitalBrussels,1090Brussels,Belgium 3Department of Immunology, Erasmus MC, 3015 CN Rotterdam, Netherlands 4Department of Pediatric Hematology, Oncology and Immunology, University Hospital Brussels, 1090 Brussels, Belgium Correspondence should be addressed to J. E. van der Werff ten Bosch; [email protected] Received 3 February 2015; Accepted 31 March 2015 Academic Editor: Jiri Litzman Copyright © 2015 M. M. G. Vollebregt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rapadilino syndrome is a genetic disease characterized by a characteristic clinical tableau. It is caused by mutations in RECQL4 gene. Immunodeficiency is not described as a classical feature of the disease. We present a 2-year-old girl with Rapadilino syndrome with important lymphadenopathies and pneumonia due to disseminated Mycobacterium lentiflavum infection. An immunological work-up showed several unexpected abnormalities. Repeated blood samples showed severe lymphopenia. Immunophenotyping showed low T, B, and NK cells. No Treg cells were seen. T cell responses to stimulations were insufficient.
    [Show full text]
  • Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders
    Comprehensive Skeletal Dysplasias and Disorders Panel Test code: MA3301 Is a 251 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of disorders involving the skeletal system. About Comprehensive Skeletal Dysplasias and Disorders This panel covers a broad spectrum of skeletal disorders including common and rare skeletal dysplasias (eg. achondroplasia, COL2A1 related dysplasias, diastrophic dysplasia, various types of spondylo-metaphyseal dysplasias), various ciliopathies with skeletal involvement (eg. short rib-polydactylies, asphyxiating thoracic dysplasia dysplasias and Ellis-van Creveld syndrome), various subtypes of osteogenesis imperfecta, campomelic dysplasia, slender bone dysplasias, dysplasias with multiple joint dislocations, chondrodysplasia punctata group of disorders, neonatal osteosclerotic dysplasias, osteopetrosis and related disorders, abnormal mineralization group of disorders (eg hypopohosphatasia), osteolysis group of disorders, disorders with disorganized development of skeletal components, overgrowth syndromes with skeletal involvement, craniosynostosis syndromes, dysostoses with predominant craniofacial involvement, dysostoses with predominant vertebral involvement, patellar dysostoses, brachydactylies, some disorders with limb hypoplasia-reduction defects, ectrodactyly with and without other manifestations, polydactyly-syndactyly-triphalangism group of disorders, and disorders with defects in joint formation and synostoses. Availability 4 weeks Gene Set Description
    [Show full text]
  • Craniosynostosis Precision Panel Overview Indications Clinical Utility
    Craniosynostosis Precision Panel Overview Craniosynostosis is defined as the premature fusion of one or more cranial sutures, often resulting in abnormal head shape. It is a developmental craniofacial anomaly resulting from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). As well, craniosynostosis can be simple when only one suture fuses prematurely or complex/compound when there is a premature fusion of multiple sutures. Complex craniosynostosis are usually associated with other body deformities. The main morbidity risk is the elevated intracranial pressure and subsequent brain damage. When left untreated, craniosynostosis can cause serious complications such as developmental delay, facial abnormality, sensory, respiratory and neurological dysfunction, eye anomalies and psychosocial disturbances. In approximately 85% of the cases, this disease is isolated and nonsyndromic. Syndromic craniosynostosis usually present with multiorgan complications. The Igenomix Craniosynostosis Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Craniosynostosis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion with or without the following manifestations: ‐ Microcephaly ‐ Scaphocephaly (elongated head) ‐ Anterior plagiocephaly ‐ Brachycephaly ‐ Torticollis ‐ Frontal bossing Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment in the form surgical procedures to relieve fused sutures, midface advancement, limited phase of orthodontic treatment and combined 1 orthodontics/orthognathic surgery treatment.
    [Show full text]
  • Absent Radius (TAR) Syndrome
    orphananesthesia Anaesthesia recommendations for patients suffering from Thrombocytopenia- Absent Radius (TAR) syndrome Disease name: Thrombocytopenia- Absent Radius (TAR) syndrome ICD 10: Q87.2 Synonyms: Absent radii and thrombocytopenia, Thrombocytopenia absent radii, Thrombocytopenia absent radius syndrome, Radial Aplasia Amegakaryocytic Thrombocytopenia, Radial Aplasia Thrombocytopenia Syndrome, Radial Aplasia- Amegakaryocytic Thrombocytopenia, TAR Syndrome. Thrombocytopenia- absent radius syndrome is an uncommon congenital malformation condition characterized by bilateral absence of the radii with the presence of thumbs, and congenital thrombocytopenia. The syndrome is phenotypically variable. It is inherited in an autosomal recessive pattern caused by a 200kb deletion including or null mutation of RBM8A on one chromosome and a non-coding polymorphism in RBM8A on the other chromosome. The estimated prevalence is between 0.5- 1:100,000 and 1:240, 000 births. It affects both sexes equally. Over 150 cases have been previously reported. Medicine in progress Perhaps new knowledge Every patient is unique Perhaps the diagnostic is wrong Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net 1 Disease summary The combination of thrombocytopenia and absent radii was first described by Greenwald and Sherman in 1929, and delineated as a syndrome with a description of cardinal manifestations by Hall et al in 1969 [1,2]. The most common clinical features are: Thrombocytopenia (100%) - symptomatic in over 90% of the cases within the first four months of life. Platelet counts are usually in the range of 15 - 30x109/L in infancy and improve to almost normal range by adulthood. The thrombocytopenia is thought to be secondary to impaired bone marrow production of platelets, despite normal thrombopoetin production and slightly elevated serum levels.The number of megakaryocytes in the bone marrow is strongly reduced.
    [Show full text]
  • Nationwide Survey of Baller‑Gerold Syndrome in Japanese Population
    3222 MOLECULAR MEDICINE REPORTS 15: 3222-3224, 2017 Nationwide survey of Baller‑Gerold syndrome in Japanese population HIDEO KANEKO1, RIE IZUMI2, HIROTSUGU ODA3, OSAMU OHARA4, KIYOKO SAMESHIMA5, HIDENORI OHNISHI6, TOSHIYUKI FUKAO6 and MICHINORI FUNATO1 1Department of Clinical Research, National Hospital Organization Nagara Medical Center, Gifu 502-8558; 2Niigata Prefecture Hamagumi Medical Rehabilitation Center for Children, Niigata 951-8121; 3Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences (RIKEN‑IMS), Yokohama, Kanagawa 230-0045; 4Department of Technology Development, Kazusa DNA Research Institute, Kisarazu, Chiba 292-0818; 5Division of Medical Genetics, Gunma Children's Medical Center, Shibukawa, Gunma 377‑8577; 6Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan Received July 19, 2016; Accepted March 10, 2017 DOI: 10.3892/mmr.2017.6408 Abstract. Baller-Gerold syndrome (BGS) is a rare autosomal mutations of the RECQL4 gene causes Rothmund-Thomson genetic disorder characterized by radial aplasia/hypoplasia syndrome (3,4). and craniosynostosis. The causative gene for BGS encodes However, mutations in the RECQL4 gene have been associ- RECQL4, which belongs to the RecQ helicase family. To ated with two other recessive disorders: One is RAPADILINO understand BGS patients in Japan, a nationwide survey was syndrome (OMIM 266280) which is characterized by radial conducted, which identified 2 families and 3 patients affected hypoplasia, patella hypoplasia and arched plate, diarrhoea and by the syndrome. All the three patients showed radial defects dislocated joints, little size and limb malformation, slender and craniosynostosis. In one patient who showed a dislocated nose and normal intelligence (4). The other is Baller-Gerold joint of the hip and flexion contracture of both the elbow syndrome (BGS) (OMIM 218600) characterized by radial joints and wrists at birth, a homozygous large deletion in the aplasia/hypoplasia and craniosynostosis (5).
    [Show full text]
  • Skeletal Dysplasias Precision Panel Overview Indications
    Skeletal Dysplasias Precision Panel Overview Skeletal Dysplasias, also known as osteochondrodysplasias, are a clinically and phenotypically heterogeneous group of more than 450 inherited disorders characterized by abnormalities mainly of cartilage and bone growth although they can also affect muscle, tendons and ligaments, resulting in abnormal shape and size of the skeleton and disproportion of long bones, spine and head. They differ in natural histories, prognoses, inheritance patterns and physiopathologic mechanisms. They range in severity from those that are embryonically lethal to those with minimum morbidity. Approximately 5% of children with congenital birth defects have skeletal dysplasias. Until recently, the diagnosis of skeletal dysplasia relied almost exclusively on careful phenotyping, however, the advent of genomic tests has the potential to make a more accurate and definite diagnosis based on the suspected clinical diagnosis. The 4 most common skeletal dysplasias are thanatophoric dysplasia, achondroplasia, osteogenesis imperfecta and achondrogenesis. The inheritance pattern of skeletal dysplasias is variable and includes autosomal dominant, recessive and X-linked. The Igenomix Skeletal Dysplasias Precision Panel can be used to make a directed and accurate differential diagnosis of skeletal abnormalities ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum
    [Show full text]
  • Download CGT Exome V2.0
    CGT Exome version 2.
    [Show full text]
  • Congenital Diseases of DNA Replication: Clinical Phenotypes and Molecular Mechanisms
    International Journal of Molecular Sciences Review Congenital Diseases of DNA Replication: Clinical Phenotypes and Molecular Mechanisms Megan Schmit and Anja-Katrin Bielinsky * Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] * Correspondence: [email protected] Abstract: Deoxyribonucleic acid (DNA) replication can be divided into three major steps: initiation, elongation and termination. Each time a human cell divides, these steps must be reiteratively carried out. Disruption of DNA replication can lead to genomic instability, with the accumulation of point mutations or larger chromosomal anomalies such as rearrangements. While cancer is the most common class of disease associated with genomic instability, several congenital diseases with dysfunctional DNA replication give rise to similar DNA alterations. In this review, we discuss all congenital diseases that arise from pathogenic variants in essential replication genes across the spectrum of aberrant replisome assembly, origin activation and DNA synthesis. For each of these conditions, we describe their clinical phenotypes as well as molecular studies aimed at determining the functional mechanisms of disease, including the assessment of genomic stability. By comparing and contrasting these diseases, we hope to illuminate how the disruption of DNA replication at distinct steps affects human health in a surprisingly cell-type-specific manner. Keywords: Meier-Gorlin syndrome; natural killer cell deficiency; X-linked pigmentary reticulate disorder; Van Esch-O’Driscoll disease; IMAGe syndrome; FILS syndrome; Rothmund-Thomson syndrome; Baller-Gerold syndrome; RAPADILINO Citation: Schmit, M.; Bielinsky, A.-K. Congenital Diseases of DNA Replication: Clinical Phenotypes and 1. Introduction Molecular Mechanisms. Int. J. Mol. 1.1. Replication Initiation Sci.
    [Show full text]
  • Identification of Novel Compound Heterozygous RECQL4 Mutations and Prenatal Diagnosis of Baller-Gerold Syndrome: a Case Report
    Case Report Identification of novel compound heterozygous RECQL4 mutations and prenatal diagnosis of Baller-Gerold syndrome: a case report D.H. Cao1*, K. Mu2*, D.N. Liu1, J.L. Sun1, X.Z. Bai1, N. Zhang1, G.B. Qiu3 and X.W. Ma1 1Aristogenesis Center, Hospital of PLA, Shenyang, China 2Genetic Disease Laboratory, Zibo Maternal and Child Health Hospital, Zibo, China 3Department of Laboratory Medicine, Hospital of PLA, Shenyang, China *These authors contributed equally to this study. Corresponding author: X.W. Ma E-mail: [email protected] Genet. Mol. Res. 14 (2): 4757-4766 (2015) Received July 8, 2014 Accepted October 29, 2014 Published May 11, 2015 DOI http://dx.doi.org/10.4238/2015.May.11.8 ABSTRACT. Birth defects are structural and/or functional malforma- tions present at birth that cause physical or mental disability and are im- portant public health problems. Our study was aimed at genetic analysis and prenatal diagnosis of congenital anomalies to understand the cause of certain birth defects. Karyotypes and array-comparative genomic hy- bridization (aCGH) were performed on a pregnant woman, surrounding amniotic fluid, and her husband. A short-stature panel genetic test was conducted in accordance with the phenotype of the fetus. Following examination, it was determined that the karyotype and aCGH results were normal. The RECQL4 gene in the fetus showed compound het- erozygous mutations, and each parent was found to be a carrier of one of the mutations. The two heterozygous mutations (c.2059-1G>C and c.2141_2142delAG) were detected in the RECQL4 (NM_004260) gene Genetics and Molecular Research 14 (2): 4757-4766 (2015) ©FUNPEC-RP www.funpecrp.com.br D.H.
    [Show full text]